Update on pharmacologic therapy for pulmonary embolism
- Prakash Harikrishnan,
- Chandrasekar Palaniswamy,
- Wilbert S. Aronow(corresponding author)
- New York Medical College
Scholary Output:
Contribution to journal
Review article
Peer-reviewAbstract
Warfarin, unfractionated heparin (UFH), and low-molecular-weight heparins are anticoagulants that have been used for treatment of pulmonary embolism. Currently approved drugs for treatment of venous thromboembolism include UFH, enoxaparin, dalteparin, fondaparinux, warfarin, and rivaroxaban. The advent of newer oral anticoagulants such as rivaroxaban, dabigatran, and apixaban has provided us with alternative therapeutic options for long-term anticoagulation. This article will give an overview of the various anticoagulant drugs, use in various clinical scenarios, data supporting their clinical use, and recommendations regarding duration of anticoagulant therapy.
Publication Information
Output type
Scholary Output:
Contribution to journal
Review article
Peer-reviewOriginal language
English (US)Pages from-to (Number of pages)
Pages 159-169 (11 pages)Journal (Volume, Issue Number)
Journal of Cardiovascular Pharmacology and Therapeutics (Volume 19, Issue 2)Publication milestones
- Published - 03/2014
Publication status
Published - 03/2014
ISSN
1074-2484Publication IDs
- Scopus: 84894448506
- PubMed: 24177334
Publication metrics
Metrics
SciVal
FWCI
0.24
SciVal
Author count
3
SciVal
citations
4
SciVal
Paper percentile
50
Fractional count
1
Fractional count
0.33
Fractional count
2
Fractional count
0.67
Fractional count
1
Fractional count
1
PlumX, opens in new tab
Usage
29
Citation count
5
Captures
39
